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Introduction
The incidence of colorectal cancer in Malaysia is increasing;
recent data collected by a local cancer registry in Malaysia
demonstrate that colorectal carcinoma is the third most
common malignancy, with an incidence of 22.5 per 100,000.1
Measures to reduce the morbidity and mortality associated
with this malignancy are being implemented primarily through
dispersion of information to the public regarding the
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BACKGROUND: Promising new pharmacological agents and gene therapy targeting cyclooxygenase-2 (COX-
2) and inducible nitric oxide synthase (iNOS) could modulate treatment of colorectal cancer in the future. The
aim of this study was to elucidate the expression of β-catenin and the presence of COX-2 and iNOS in colorectal
cancer specimens in Malaysia. This is a useful prelude to future studies investigating interventions directed
towards COX-2 and iNOS.
METHODS: A cross-sectional study using retrospective data over a 2-year period (1999–2000) involved 101
archival, formalin-fixed, paraffin-embedded tissue samples of colorectal cancers that were surgically resected in
a tertiary referral centre.
RESULTS: COX-2 production was detected in adjacent normal tissue in 34 samples (33.7 %) and in tumour tissue
in 60 samples (59.4%). More tumours expressed iNOS (82/101, 81.2%) than COX-2. No iNOS expression was
detected in adjacent normal tissue. Intense β-catenin immunoreactivity was found in both the cytoplasm and
nuclei of tumour cells, with a distinct loss of β-catenin immunoreactivity at the cell-to-cell border. Poorly
differentiated tumours had significantly lower total β-catenin (p = 0.009) and COX-2 scores (p = 0.031). No
significant relationships were established between pathological stage and β-catenin, COX-2 and iNOS scores.
CONCLUSIONS: The accumulation of β-catenin does not seem to be sufficient to activate pathways that lead
to increased COX-2 and iNOS expression. A high proportion of colorectal cancers were found to express COX-
2 and a significant number produced iNOS, suggesting that their inhibitors may be potentially useful as
chemotherapeutic agents in the management of colorectal cancer. [Asian J Surg 2004;27(1):10–7]
importance of seeking early medical advice and via increasing
use of endoscopic evaluation. It is imperative, however, for
these measures to be supplemented with newer strategies and
interventions, apart from surgery, to produce a dramatic
improvement in the outcome or survival of patients with
colorectal cancer.
Vogelstein’s colorectal cancer model outlines at least four
sequential mutational changes, including mutations in the
adenomatous polyposis coli (APC) gene, which is the earliest
© 2004 Elsevier. All rights reserved.
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genetic mutation to occur,2 K-ras, “deleted in colorectal can-
cer” (DCC), and p53.3,4 APC is necessary for the formation of
complexes between glycogen synthase kinase (GSK)-3β and β-
catenin. β-Catenin is the target for degradation by the ubiquitin-
proteosome pathway.5 Functional loss of APC by genetic
mutations in colorectal cancer causes the accumulation of β-
catenin.6 β-Catenin can then translocate into the nucleus
where it binds to the T-cell factor (TCF)/lymphoid enhancer
factor (LEF) family of proteins and activates many genes such
as c-myc, cyclin D1, matrix metalloproteinase, cyclooxygenase-
2 (COX-2), and inducible nitric oxide synthase (iNOS).7
COX-2, an enzyme involved in the conversion of arachidonic
acid to prostaglandins, is induced by inflammatory and
mitogenic stimuli. Thus, the synthesis of prostaglandins is
increased in inflamed and neoplastic tissues.8 There is ample
evidence suggesting that COX-2 expression is important in
carcinogenesis.9 Selective COX-2 inhibitors can interfere with
tumorigenesis in experimental systems including colorectal
cancer.10 Accumulating evidence indicates that non-steroidal
anti-inflammatory drugs (NSAIDs) can reduce the mortality
rate by 40% to 50%,11 decrease cell proliferation to give smaller
tumours,12 and reduce the number of intestinal polyps.13
NSAIDs reduce the number and size of polyps in patients with
familial adenomatous polyposis.14 Selective COX-2 inhibitors
may play an important role in the management of colorectal
cancer in the future.
Nitric oxide synthase catalyzes the synthesis of nitric oxide
(NO) from L-arginine.15 Both iNOS and NO have been reported
in various cancers, including colorectal carcinoma.16 NO is a
highly reactive free radical and short-lived molecule that is
involved in many tumour-promoting functions,17–19 suggest-
ing that iNOS inhibitors may also have therapeutic value in
treating colorectal cancer.
We investigated 101 paired colorectal carcinoma tissues
for β-catenin, COX-2 and iNOS expression to determine the
correlation between expression of these molecules and to
determine the frequency of COX-2 and iNOS expression, to
assess the clinical relevance of new pharmacological agents
and gene therapy targeting COX-2 and iNOS. This is the first
study in this country to investigate the presence of COX-2 and
iNOS in colorectal carcinoma.
Materials and methods
Tissue specimens
This was a cross-sectional study using retrospective data from
101 archival, formalin-fixed, paraffin-embedded tissue samples
of colorectal carcinoma that were surgically resected at the
Kuala Lumpur Hospital, Malaysia, between 1999 and 2000.
None of the patients had received neoadjuvant therapy prior
to surgery and none had a known family history of colorectal
cancer. Only primary colorectal carcinomas were included. A
number of paraffin blocks were made for each surgically
resected tumour. Archival haematoxylin and eosin-stained
slides were retrieved to find the section that contained the bulk
of the tumour, which was representative of the tumour and the
paired adjacent normal tissue. The respective tissue blocks
were then sectioned at 4 µm and mounted on glass slides
coated with 3-aminopropyltrimethoxysilane (Aldrich Chemical
Company, Milwaukee, WI, USA).
Primary antibodies
Three primary antibodies were used. The anti-β-catenin
monoclonal antibody was raised against a peptide corres-
ponding to amino acids 571–781 at the carboxyl terminus of
β-catenin (clone 14; Transduction Laboratories, Lexington,
KY, USA) and used at a 1:200 dilution. Anti-COX-2 monoclonal
antibody was raised against a peptide corresponding to amino
acids 368–604 of COX-2 (clone 33; Transduction Laboratories)
and used at a 1:50 dilution. The anti-iNOS monoclonal
antibody was reactive against a peptide corresponding to
amino acids 961–1144 of iNOS (clone 6; Transduction
Laboratories) and it was used at a dilution of 1:100.
Immunohistochemistry
Prior to immunohistochemical staining, sections were
deparaffinized and rehydrated using standard procedures.
Antigen retrieval was performed using heat treatment;
endogenous peroxidase activity was blocked by incubation
with 3% hydrogen peroxide (Ajax Chemicals, Auburn, NSW,
Australia) for 10 minutes. To block non-specific antigen sites,
tissue sections were incubated for 1 hour in 1.5% bovine serum
albumin (Fluka BioChemika, Deisenhofen, Germany) at room
temperature. Incubation with the primary antibodies was
performed at room temperature for 30 minutes with anti-β-
catenin, and 60 minutes with the anti-COX-2 and anti-iNOS
antibodies. After the primary antibody incubation step, a
secondary antibody from a streptavidin biotin complex
peroxidase kit (LSAB® + kit, Dako, Copenhagen, Denmark)
was used according to the manufacturer’s instructions with
minor modifications. For sections incubated with anti-β-
catenin, both the linking antibody and streptavidin peroxidase
complex from the LSAB® + kit were incubated consecutively
for 15 minutes. For the remaining antibodies, the incubation
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period was 30 minutes. Peroxidase activity was developed with
the substrate 3,3’-diaminobenzidine tetrahydrochloride (DAB;
Dako) by incubating the sections in DAB for 10 minutes.
Sections were then rinsed gently with distilled water and
counterstained with haematoxylin. Negative controls were
prepared simultaneously for all 101 samples by replacing the
primary antibody with distilled water. Thus, each tumour
slide had its own negative control.
Evaluation of immunohistochemical staining
At least three fields were randomly selected for each section. A
modified semi-quantitative scoring system was used to evaluate
staining (Table 1).15,20 The percentage of positive cells and the
strength of staining intensity were evaluated for the samples
and negative controls. The score for each area was the sum of
the percentage of positive cells and strength of staining
intensity. A final total score was generated by subtracting the
score in the sample from the score in the negative control. The
minimum and maximum score for a sample were 0 and 7,
respectively. The evaluation was performed by two independent
researchers, one of whom was a medically qualified histo-
pathologist, to ensure precision and accuracy.
Statistical analysis
The average total scores are reported as the mean rank and
median score. Since the total score was not normally distributed,
the association between immunohistochemical score and
clinicopathological features was analysed using the Mann-
Whitney U test or Kruskal-Wallis one-way analysis of variance
by ranks. The Spearman rank correlation test was used to
analyse the correlation of β-catenin, COX-2 and iNOS
expression with each other. A p value of less than 0.05 was
considered significant. Statistical analysis was performed using
SPSS for Windows version 10.0 (SPSS Inc, Chicago, IL, USA).
Results
Table 2 shows the clinicopathological data of the cases in this
study. The study included samples from 59 male and 42 female
patients with ages ranging from 23 to 87 years. Fifty-five
patients were of Chinese origin and 46 were non-Chinese. Of
the 101 cancers, 80 (79.2%) were moderately differentiated, 13
(12.9%) were well differentiated, and eight (7.9%) were poorly
differentiated.
Analysis of β-catenin immunoreactivity
Positive immunoreactivity for β-catenin was detected in all
101 samples. In normal adjacent tissue, it was mainly localized
Table 2. Clinicopathological data of patients (N = 101)
Patient characteristic n
Gender
   Male 59
   Female 42
Age
   Range, 23–87 yr
   Median, 63 yr
      < 40 yr 4
      ≥ 40 yr 97
Race
   Chinese 55
   Non-Chinese 46
Pathological stage (Astler-Coller classification)
   A 4
   B1 6
   B2 45
   C1 4
   C2 42
Histological grade
   Well differentiated 13
   Moderately differentiated 80
   Poorly differentiated 8
Tumour site
   Left colon 57
   Right colon 24
   Rectum 20
Table 1. Scoring system for immunohistochemical staining,
adapted from previous reports15,20
Evaluation of % Evaluation of
positive cells stain intensity
0 no staining 0 no staining
1+ < 25% positive 1+ mild staining
2+ 25–50% positive 2+ moderate staining
3+ 50–75% positive 3+ intense staining
4+ > 75% positive
Score for a tumour area (A) = score for % positive cells + score for
stain intensity
Score for negative control of similar tumour tissue area (B) = score
for % positive cells + score for stain intensity
Total score = A – B
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in the plasma membrane of the cell-to-cell border and in the
cytoplasm of both the colonic epithelium and goblet cells
(Figure 1A). No nuclear β-catenin was seen in the normal
colonic mucosa. However, in colorectal carcinoma tissue, β-
catenin immunoreactivity was found to be markedly intense
in both the cytoplasm and nuclei of tumour cells from all 101
cases (Figure 1B). Both loss of and reduced β-catenin
immunoreactivity in the cell-to-cell border were observed.
COX-2 and iNOS immunoreactivity
COX-2 immunoreactivity was detected in adjacent normal
tissue in only 33.7% (34) of samples (Figure 2A) compared to
59.4% (60) in tumour tissue (Figure 2B). In all positive cases,
COX-2 immunoreactivity was located in the cytoplasm,
although some endothelial and stromal cells found at the
tumour site were also weakly reactive.
iNOS immunoreactivity was not detected in adjacent
normal tissue in any samples (Figure 2C), in contrast to positive
immunoreactivity in tumour tissue in 81.2% of samples (Figure
2D). The immunoreactivity was located in the cytoplasm of
tumour cells, especially at the apical surfaces of cells forming
a glandular pattern. Very weak immunoreactivity was detected
in endothelial and smooth muscle cells found at or near the
tumour site.
A B
Figure 1. Immunohistochemical staining for β-catenin is detected at: A) the cell-to-cell border of the plasma membrane and in the
cytoplasm of adjacent normal tissue; B) in both the cytoplasm and nuclei of tumour tissue.
Figure 2. Representative slides showing immunohistochemical staining for cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase
(iNOS). A) COX-2 immunoreactivity is detected in the cytoplasm of normal adjacent colonic tissue (x 100) and B) colorectal carcinoma
tissue (x 200). C) There is no iNOS staining in normal adjacent colonic tissue (x 100) but D) iNOS is present in the tumour (x 100).
A
C
B
D
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The correlation between total scores for β-catenin, COX-2
and iNOS is shown in Table 3. Using the Spearman rank
correlation test, we found that total β-catenin, COX-2 and
iNOS scores were significantly related to each other. There was
a positive linear relationship between total β-catenin score and
both total COX-2 score and total iNOS score. There was also
a significant positive linear relationship between COX-2 and
iNOS scores.
Correlations between total immunoreactivity scores and patient
characteristics
There was no significant correlation between gender and total
β-catenin, COX-2 and iNOS scores (Table 4). There was no
significant correlation between age or race and total β-catenin,
COX-2 and iNOS scores (data not shown).
Correlations between total immunoreactivity scores and
tumour characteristics
No statistically significant correlations were established
between pathological stage (Astler-Coller classification) and
Table 5. Correlation between pathological stage (Astler-Coller classification) and total β-catenin, cyclooxygenase-2 (COX-2) and
inducible nitric oxide synthase (iNOS) scores
Astler-Coller classification
A (n = 4) B1 (n = 6) B2 (n = 45) C1 (n = 4) C2 (n = 42) p
Mean β-catenin rank 39.50 37.33 56.29 57.75 47.74 0.333
Mean COX-2 rank 62.38 49.08 55.27 31.38 47.49 0.366
Mean iNOS rank 54.88 56.17 53.83 56.50 46.33 0.709
Kruskal-Wallis one-way analysis of variance by ranks. p < 0.05 indicates statistical significance.
Table 4. Correlation between gender and total β-catenin,
cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase
(iNOS) scores
Male Female p
(n = 59) (n = 42)
Mean β-catenin rank 52.34 49.12 0.566
Mean COX-2 rank 48.83 54.05 0.359
Mean iNOS rank 49.97 52.45 0.654
Mann-Whitney U-test. p < 0.05 indicates statistical significance.
Table 3. Correlation among total β-catenin, cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) scores
β-catenin score COX-2 score iNOS score
β-catenin score
r — 0.323 0.371
p — 0.001 < 0.05
COX-2 score
r 0.323 — 0.393
p 0.001 — < 0.05
iNOS score
r 0.371 0.393 —
p < 0.05 < 0.05 —
Spearman rank correlation test. A 2-sided p < 0.05 indicates statistical significance.
total β-catenin, COX-2 and iNOS scores (Table 5). Total β-
catenin (p = 0.009, Kruskal-Wallis one-way analysis of variance
by ranks) and COX-2 (p = 0.031) scores were statistically
significantly associated with histological grade (Table 6). In
general, poorly differentiated tumours had significantly lower
total β-catenin and COX-2 immunohistochemical scores. There
was no significant correlation between tumour site and total
COX-2 and iNOS scores (Table 7). Tumours found in the left
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colon and rectum had significant total β-catenin scores,
whereas tumours in the right colon did not.
Discussion
β-Catenin is a critical signal transducer in the Wnt/Wingless
pathway that regulates cell growth, morphogenesis, organ
development and cancer development.21 The localization of β-
catenin immunoreactivity to the plasma membrane and cell-
to-cell border of the normal colonic mucosa is consistent with
the findings of Iwamoto et al.22 This is not surprising; β-
catenin binds to the cytoplasmic tail of β-catenin, E-cadherin
and, indirectly, to the cytoskeleton, so it is localized to the
adherens junction of the cell-to-cell plasma membrane.6
Formation of multiprotein complexes consisting of
proteins such as APC, GSK-3β, axin and β-catenin makes β-
catenin a target for degradation, so that no cytoplasmic or
nuclear β-catenin will be detected in normal tissue. Our data
indicate that the amount of β-catenin is increased in both the
cytoplasm and nuclei of all colorectal carcinoma tissue, as
shown by the increased intensity of immunostaining. This
could be due to the inability of GSK-3β to phosphorylate β-
catenin, or to mutations in the genes encoding the proteins
that form the multiprotein complexes, which will result in the
accumulation of cytoplasmic β-catenin and translocation to
the nucleus.23 Furthermore, mutations in E-cadherin may also
cause the dissociation of β-catenin from the E-cadherin–β-
catenin complex, resulting in the release of unbound β-catenin
into the cytoplasm and subsequent translocation to the
nucleus. Once in the nucleus, β-catenin can interact with
members of the TCF/LEF DNA-binding family and induce the
expression of c-myc, cyclin D1 and matrilysin, which are
responsible for tumour proliferation and malignant
progression.23–25 Other examples of genes that are
transcriptionally activated include COX-2 and iNOS.26 Our
results show, for the first time, the presence of accumulated
cytoplasmic and nuclear β-catenin in colorectal carcinoma
specimens in Malaysia. They concur with those reported
previously.21,22 We need to further investigate the reasons for
the inhibition of β-catenin degradation in our colorectal
carcinoma specimens.
Immunoreactivity to COX-2, detected in 59.4% of
specimens in our study, was less frequent than in previous
studies, which report positivity in as much as 85% to 90% of
samples.27,28 Only 33.7% of samples demonstrated increased
COX-2 production in adjacent normal tissue. The reason for
the increased production of COX-2 by these apparently normal
cells is not clear. It is possible that the presence of soluble
factors in the tumour microenvironment could have
contributed to this increased COX-2 expression. The positive
COX-2 immunoreactivity in our study further supports the
role of COX-2 in carcinogenesis. COX-2 intermediates are
Table 6. Relationship of total β-catenin, cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) scores to histological
grade
Histological grade
Well differentiated Moderately Poorly p
(n = 13) differentiated (n = 80) differentiated (n = 8)
Mean β-catenin rank 52.35 53.67 22.06 0.009
Mean COX-2 rank 63.00 51.19 29.63 0.031
Mean iNOS rank 54.65 52.41 31.00 0.096
Kruskal-Wallis one-way analysis of variance by ranks. p < 0.05 indicates statistical significance.
Table 7. Relationship of total β-catenin, cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) scores to tumour site
Tumour site
Left colon (n = 57) Right colon (n = 24) Rectum (n = 20) p
Mean β-catenin rank 55.29 36.85 55.75 0.017
Mean COX-2 rank 54.79 49.52 41.97 0.207
Mean iNOS rank 54.63 47.90 44.38 0.291
Kruskal-Wallis one-way analysis of variance by ranks. p < 0.05 indicates statistical significance.
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highly reactive molecules that can derivatize DNA and oxidize
certain compounds such as oestrogens into mutagens.29 Hence,
COX-2 and its by-products of arachidonic acid metabolism
may contribute to the “genetic stability” and malignant
progression of tumour cells.
The absence of COX-2 in the nucleus is consistent with the
results of some studies,30,31 but not with those of other studies
where both cytoplasm and nuclear membranes were positive.32
We have yet to elucidate whether COX-2 is the downstream
target of the Wnt signalling pathway in both normal and
tumour tissue in our colorectal carcinoma cases. The alternative
pathway for induction of COX-2 expression is the nuclear
factor (NF)-κβ signalling pathway.33 Overexpression of β-
catenin alone has no effect on COX-2 gene expression, which
suggests a Wnt signalling pathway that cannot be mimicked
by β-catenin expression.34 This may explain our finding that
40.6% of our samples did not express COX-2 in tumour cells,
although there was an accumulation of β-catenin in the
cytoplasm and nucleus.
Our findings of iNOS production are similar to those of
previous studies. iNOS has been reported in macrophages,
vascular smooth muscle and a human colonic adenocarcinoma
cell line.35–37 Takahashi et al reported iNOS expression in rat
colonic carcinoma epithelial cells, especially at the luminal
surfaces of cancer cells, forming a glandular pattern, with all
rat colonic epithelium testing positive.31 This differs from our
findings in human cells, where 81.2% of colorectal cancer
specimens demonstrated positive iNOS expression. This
difference may be due to the fact that chemical-induced
carcinogenesis in experimental animal models is not identical
to human colorectal carcinoma. iNOS expression in the tumour
cells and surrounding stroma may result from interferon γ,
tumour necrosis factor and other cytokines produced by
tumour cells or inflammatory cells at the tumour site, since
the activation of the NF-κβ signalling pathway by certain
cytokines can also induce iNOS expression.38 Further studies
are required, however, to ascertain the reasons for the increased
iNOS production.
No significant relationship was found between gender, age
or race and total β-catenin, COX-2 and iNOS scores. This
agrees with the findings of a previous study that there was no
significant correlation between COX-2 expression and gender
or age.32 We failed to establish statistically significant
relationships between pathological grade and total β-catenin,
COX-2 and iNOS scores, even though the total β-catenin and
COX-2 scores were at the higher end for well-differentiated
tumours. The latter finding should be interpreted with caution
as a large number of specimens in this study were moderately
differentiated (79.2%) while few were well differentiated or
poorly differentiated. The localization of β-catenin was both
cytoplasmic and nuclear, irrespective of the state of
differentiation. Our results are similar to those of one study
which showed that low-grade adenomas have lower nuclear
localization scores,39 but contrast with those of another study
which reported that the most significant correlation of nuclear
β-catenin was not with dysplasia grade but with tumour size.40
We were not able to use these results to determine the
prognosis because we were unable to access the data for patients
who were subsequently followed. Because the evaluation of
immunohistochemical staining intensity can be subjective,
two researchers independently evaluated the sections and
counter-checked them to obtain accurate results. In addition,
negative controls for each section were included in all
immunostaining experiments. Our current findings need to
be supplemented with Western blotting. Each tumour speci-
men is heterogeneous and one limitation of the study is that
results presented were mostly from one section per specimen.
To counteract this, we took care to select blocks that contained
the bulk of the tumour with adjacent apparently normal
tissue, as determined by a qualified histopathologist using
microscopy.
A high proportion (59.4%) of colorectal cancers in our
population produced COX-2 and an even higher proportion
produced iNOS (81.2%). Our results suggest that there is a
possibility that COX-2 and iNOS inhibitors may be useful as
chemotherapeutic agents in the treatment of colorectal
carcinoma in some of our patients. In addition, our study
suggests that the overexpression of β-catenin is not sufficient
to induce COX-2 and iNOS gene expression since 40.6% and
18.8% of tumour cells did not express COX-2 and iNOS,
respectively, even though β-catenin had accumulated. It is
likely that additional events need to occur for induction of
COX-2 and iNOS expression and further investigation is
warranted to better understand the pathogenesis of this disease.
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